|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.155 USD | +1.78% |
|
-0.49% | -36.23% |
| 15/05 | HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating | MT |
| 14/05 | Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 |
Effective June 19, 2013, Dr. Thomas Spector resigned as Chief Scientific Officer of Adherex Technologies Inc., and entered into a Separation and Mutual Release Agreement with the company.
| 1st Jan change | Capi. | |
|---|---|---|
| -36.23% | 20Cr | |
| +8.38% | 11TCr | |
| +10.13% | 10TCr | |
| -11.69% | 2.25TCr | |
| +1.11% | 2.26TCr | |
| -11.07% | 1.8TCr | |
| -41.90% | 1.65TCr | |
| -16.00% | 1.58TCr | |
| +2.28% | 1.35TCr | |
| +20.54% | 1.1TCr |
FENNEC PHARMACEUTICALS INC. 
